<DOC>
	<DOCNO>NCT01470261</DOCNO>
	<brief_summary>The aim ADDUCE project investigate adverse effect methylphenidate ( trade name ritalin ) growth , neurological system , psychiatric state cardiovascular system two year period child adult .</brief_summary>
	<brief_title>Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects</brief_title>
	<detailed_description>Attention deficit hyperactivity disorder ( ADHD ) one common neurodevelopmental disorder child , affect approximately 5 % child Europe . Methylphenidate ( MPH , trade name ritalin ) most-commonly prescribed medication ADHD child ; also increasingly use ADHD adult . In 2007 , European Commission request referral Committee Medicinal Products Human Use ( CHMP ) Article 31 Directive 2001/83/EC , amend , MPH safety concern . The CHMP conclude study long-term effect MPH growth , sexual development , neurological system , psychiatric state cardiovascular system need . In response CHMP concern , ADDUCE ( Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects ) research team form consortium expert field ADHD , drug safety , neuro-psychopharmacology cardiovascular research . The ADDUCE project aim investigate long-term adverse effect MPH growth , neurological system , psychiatric state cardiovascular system child adult . Furthermore ADDUCE team develop research tool evaluation adverse effect MPH cognition motivation .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>ADHDtreated group : Clinical diagnosis ADHD Aged 5 17 year . Not previously treat methylphenidate Agreement clinician , patient family commence methylphenidate ( baseline measure take first prescription methylphenidate issue ) . Any comedication dexamfetamine atomoxetine allow . All psychiatric physical illness comorbidities allow ADHDunmedicated control : Clinical diagnosis ADHD previously treat medication . Aged 5 17 year . Agreement clinician , patient family treat methylphenidate . Any medication dexamfetamine atomoxetine allow . All comorbidities allow . NonADHD control : Child ADHD . Aged 5 17 year . Mean total clinician rat Swanson Nolan Pelham IV Rating scale ( SNAP IV ) score ( ADHD item ) &lt; 1.5 Parent rat Strengths Difficulties Questionnaire ( SDQ ) Hyperactivity Score within normal range country ( e.g . &lt; 6 UK ) Any current medication dexamfetamine atomoxetine allow . Must never take methylphenidate Any mental health physical illness diagnosis allow . All Groups : Current past treatment dexamfetamine atomoxetine . Unmedicated ADHD control : Previous current treatment methylphenidate . NonADHD control : Previous current treatment methylphenidate . Clinician rat SNAP score â‰¥ 1.5 . Parent rat SDQ Hyperactivity Score Borderline Abnormal range .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>methylphenidate</keyword>
	<keyword>ritalin</keyword>
	<keyword>Attention Deficit Disorder</keyword>
</DOC>